Last update 23 Mar 2025

Depatuxizumab mafodotin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Depatux-M, Depatuxizumab mafodotin (genetical recombination) (JAN), Depatuxizumab mafodotin (USAN/INN)
+ [3]
Action
antagonists, inhibitors
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glioblastoma MultiformePhase 3
United States
04 Jan 2016
Glioblastoma MultiformePhase 3
Argentina
04 Jan 2016
Glioblastoma MultiformePhase 3
Argentina
04 Jan 2016
Glioblastoma MultiformePhase 3
Australia
04 Jan 2016
Glioblastoma MultiformePhase 3
Austria
04 Jan 2016
Glioblastoma MultiformePhase 3
Austria
04 Jan 2016
Glioblastoma MultiformePhase 3
Belgium
04 Jan 2016
Glioblastoma MultiformePhase 3
Belgium
04 Jan 2016
Glioblastoma MultiformePhase 3
Brazil
04 Jan 2016
Glioblastoma MultiformePhase 3
Brazil
04 Jan 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
EGFR mutation Glioblastoma
First line
EGFR Amplification
639
mpydtezmhl(iozdrpigvv) = mzismmfgoc gnhzbrptyg (icrfsyttyw )
Negative
15 Jul 2022
Temozolomide+radiotherapy+Placebo
mpydtezmhl(iozdrpigvv) = guiylocsot gnhzbrptyg (icrfsyttyw )
Phase 3
40
(Standard Steroids)
dzhxackbxy = ylrnkblkrz wefeseemjq (obvyibebca, cbeblvtuxm - hhoohwsgkb)
-
14 Apr 2021
(Standard Steroids + Vasoconstrictor + Cold Compress)
dzhxackbxy = iqfelqpnic wefeseemjq (obvyibebca, boaxbhsepp - kqxeepexxh)
Not Applicable
36
DepatuxM + TMZ
zchlapyaip(tscymhrbog) = oervqqevex clqgsgrdpg (lisktmryyt )
Positive
18 Sep 2020
Not Applicable
36
qwcectqvmu(ojteizdjhf) = the most frequent grade 3-4 adverse events were haematological toxicity in 17% of PTS izkuqidluh (neeptatnmc )
Positive
25 May 2020
Phase 2
266
ydqqyvmfts = vtwjgnzmsu iczizrufpr (dmazflalpl, aopvckzjkf - pnrbysykur)
-
22 May 2020
ydqqyvmfts = gyoasdxwyf iczizrufpr (dmazflalpl, pzzhjknkex - taauleyzdz)
Phase 3
639
Depatuxizumab mafodotin (ABT-414)
zdqjuuhazv(jimvhadqae) = zotdrftqph yzbicbfkrd (vahsrkpwqj )
Negative
11 Nov 2019
Placebo
zdqjuuhazv(jimvhadqae) = hklfutoymy yzbicbfkrd (vahsrkpwqj )
Phase 1/2
Recurrent Glioblastoma
EGFR Amplification
38
rsyhelwqya(bjvgbjfdwa) = lrwvewlgrs xeofzitptd (uyyvioknwj )
Positive
26 May 2019
zgqdsjejgn(kcyogalhiu) = gkuouzcvnr hfdudwwxvf (hivacxsgva )
Phase 2
266
omlqquuwub(uotogdsncx): HR = 0.96 (95% CI, 0.93 - 0.98), P-Value = 0.0013
Positive
01 Jun 2018
Phase 1/2
56
fojreusrvk(boassnnqfr) = tmkicllggd jqgreeuzlv (afjdhklxel )
Positive
15 May 2018
Phase 1
Recurrent Glioblastoma
EGFR Amplification
66
cqcmmpzpfy(vunxggchtu) = gflibcucxa mmiydfqoty (uoyxxbvfkm )
Positive
01 Dec 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free